PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 14, 2026Oncology

Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAmna GameilRGRola GhasoubNJNeda Jafari

Discussion

Loading...

Member takes

Overview

Systematic review evaluates safety of anticoagulants with tyrosine kinase inhibitors in CML, indicating feasible drug combinations and monitoring for adverse events.

Key Points

  • To evaluate the safety profiles of anticoagulants combined with tyrosine kinase inhibitors in chronic myeloid leukemia management.
  • Conducted a systematic review of studies addressing anticoagulant and TKI combinations in CML.
  • Employed a comprehensive search strategy across PubMed, Medline, Embase, and Web of Science.
  • Data extraction was done using standardized forms and study quality was assessed with CASP and JBI tools.
  • 13 studies reported real-world safety data for TKIs with anticoagulants.
  • No major bleeding complications observed in TKI-anticoagulant combinations like ponatinib with apixaban.
  • Pharmacokinetic interactions, particularly between nilotinib and warfarin, were noted but deemed manageable.

Cite This Study

Gameil et al. (2026) studied this question.

synapsesocial.com/papers/6966f30613bf7a6f02c008c4https://doi.org/10.1159/000550346
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tyrosine kinase inhibitors and secondary malignancies in chronic myeloid leukemia: A protocol for systematic review2025
  2. 2A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors2022 · 5 citations
  3. 3Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors2022 · 2 citations
  4. 4Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study2026
  5. 5Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing2018 · 90 citations